Regeneron Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>RP</div>
REGN -- USA Stock  

USD 453.19  5.41  1.18%

Regeneron Pharmaceuticals is scheduled to announce its earnings today. The next earnings report is expected on the 4th of May 2021. As many retail investors are getting excited about healthcare space, it is fair to outline Regeneron Pharmaceuticals outlook under the latest economic conditions. We will evaluate if Regeneron Pharmaceuticals shares are reasonably priced given the latest economic outlook.
Published over two weeks ago
View all stories for Regeneron Pharmaceuticals | View All Stories
What is March outlook for Regeneron Pharmaceuticals (NASDAQ:REGN)?
The company currently holds 2.69 B in liabilities with Debt to Equity (D/E) ratio of 0.27, which may suggest Regeneron Pharmaceuticals is not taking enough advantage from borrowing.
What is the right price you would pay to acquire a share of Regeneron Pharmaceuticals? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

What is happening with Regeneron Pharmaceuticals this year

Annual and quarterly reports issued by Regeneron Pharmaceuticals are formal financial statements that are published yearly and quarterly and sent to Regeneron stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Regeneron Pharmaceuticals often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Regeneron utilizes its cash?

To perform a cash flow analysis of Regeneron Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Regeneron Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Regeneron Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Regeneron Pharmaceuticals Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at 2.82 Billion

Exercise or conversion by Vagelos P Roy of 248079 shares of Regeneron Pharmaceuticals subject to Rule 16b-3

Legal trades by Regeneron Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Regeneron insider trading alert for exercise of non-qualified stock option (right to buy) by Vagelos P Roy, the corporate stakeholder, on 24th of February 2021. This event was filed by Regeneron Pharmaceuticals with SEC on 2021-02-24. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Regeneron a risky opportunity?

Let's check the volatility. Regeneron is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Regeneron (NASDAQ:REGN) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. picking up a share of a Regeneron Pharmaceuticals stock makes you a part-owner of that company.

Regeneron Pharmaceuticals Current Consensus

Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering Regeneron Pharmaceuticals. The Regeneron consensus assessment is calculated by taking the average estimates from all of the analysts covering Regeneron Pharmaceuticals

Strong Buy
Strong Buy1470.0
Strong Sell00.0

Will Regeneron continue to rise?

The information ratio is down to -0.21 as of today. Regeneron Pharmaceuticals exhibits very low volatility with skewness of 0.23 and kurtosis of 0.95. However, we advise investors to further study Regeneron Pharmaceuticals technical indicators to make sure all market info is available and is reliable.

Our Final Take On Regeneron Pharmaceuticals

Whereas some other entities in the biotechnology industry are either recovering or due for a correction, Regeneron may not be as strong as the others in terms of longer-term growth potentials. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither take over nor trade any shares of Regeneron Pharmaceuticals at this time. The Regeneron Pharmaceuticals risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Regeneron Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Regeneron Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to